Savara (SVRA) Current Deferred Revenue (2018 - 2020)

Savara (SVRA) reported Current Deferred Revenue of $243000.0 for Q2 2020, up 2.1% quarter-over-quarter from $238000.0 in Q1 2020.

Savara (SVRA) Current Deferred Revenue (2018 - 2020) Analysis & Trends

Savara (SVRA) has 3 years of Current Deferred Revenue data on file, last reported at $243000.0 in Q2 2020.

  • Current Deferred Revenue for Q2 2020 came in at $243000.0, changed N/A year-over-year; the trailing twelve-month figure through Jun 2020 was $243000.0 (changed N/A YoY), and the FY2018 annual result was $250000.0, changed N/A from the prior year.
  • Current Deferred Revenue climbed to $243000.0 in Q2 2020 per SVRA's latest filing, from $238000.0 in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $250000.0 in Q4 2018 and troughed at $238000.0 in Q1 2020.
  • A 3-year average of $243250.0 and a median of $242500.0 in 2019 frame the typical range for Current Deferred Revenue.
  • On a YoY basis, Current Deferred Revenue climbed as much as 1.65% in 2020 and fell as far as 1.65% in 2020.
  • A 3-year view of Current Deferred Revenue shows it stood at $250000.0 in 2018, then slipped by 3.2% to $242000.0 in 2019, then increased by 0.41% to $243000.0 in 2020.
  • Business Quant data shows SVRA's Current Deferred Revenue at $243000.0 in Q2 2020, $238000.0 in Q1 2020, and $242000.0 in Q1 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Savara 1.39 Bn 1.39 Bn -

Historic Data

Download Data
DateValue
Jun 30, 2020 243,000.00
Mar 31, 2020 238,000.00
Mar 31, 2019 242,000.00
Dec 31, 2018 250,000.00